CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for ...

CLEVELAND, OH — The age/sex/gene-expression score (ASGES) test known as Corus CAD (CardioDx) appears easy to incorporate and effective in excluding obstructive coronary artery disease (CAD) in ...

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for ...

Patients With a Low Corus CAD Score Had 94% Reduced Odds of Referral to a Cardiologist; REGISTRY I Study Results Add to the Established Evidence Base Supporting the Clinical Utility of the Corus CAD ...

REDWOOD CITY, CA--(Marketwired - Oct 20, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of a ...

Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Evaluation of Obstructive Coronary Artery Disease REDWOOD CITY, Calif. – CardioDx, Inc., a molecular diagnostics company ...

It's been a difficult year for CardioDx, but there may be light at the end of the tunnel: In a new study, researchers found that the company's genetic test for coronary artery disease could help ...

PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the American Heart Journal. The paper ...